MOG (35-55) Peptide: Benchmark Inducer in Autoimmune Encephalomyelitis

Executive Summary: MOG (35-55) is a human myelin oligodendrocyte glycoprotein peptide widely used to induce experimental autoimmune encephalomyelitis (EAE), a preclinical model of multiple sclerosis (MS) (APExBIO product page). This peptide, corresponding to amino acids 35–55 of MOG, triggers both T and B cell-mediated immune responses, leading to chronic demyelinating disease in genetically susceptible mouse strains (Xu et al., 2025). MOG (35-55) is highly soluble in water and DMSO, but not in ethanol, and is typically administered subcutaneously at 50–150 μg per animal in conjunction with adjuvant. Its use has yielded highly reproducible EAE models, facilitating mechanistic studies and therapeutic screening for MS. Recent molecular insights reveal that pathways such as type I interferon signaling, modulated by factors like PARP7, are critical in EAE pathology and can be interrogated using MOG (35-55)-based models.

Biological Rationale

MOG (35-55) peptide is derived from the extracellular domain of myelin oligodendrocyte glycoprotein, a CNS-specific antigen with a pivotal role in myelin sheath stability. In EAE models, this peptide reproduces key immunopathological features of MS, including CNS-specific inflammation, demyelination, and motor deficits (see comparative review). The utility of MOG (35-55) in preclinical research arises from its capacity to selectively activate autoreactive CD4+ T helper cells, which initiate and propagate neuroinflammatory cascades characteristic of human MS (Xu et al., 2025). Genetic background, such as HLA-DR2 or C57BL/6, strongly influences the penetrance and chronicity of EAE, allowing for precise modeling of relapsing-remitting or progressive disease courses. This model bridges the gap between basic immunopathology and translational intervention studies, underpinning its routine application in autoimmune encephalomyelitis research.

Mechanism of Action of MOG (35-55) Peptide

MOG (35-55) acts as an encephalitogenic peptide. Upon administration with complete Freund's adjuvant (CFA), it is taken up by antigen-presenting cells and presented on MHC class II molecules. This activates naive T cells, particularly Th1 and Th17 subsets, which infiltrate the CNS and mediate demyelination. B cell responses lead to anti-MOG antibodies, further contributing to myelin damage. Extensive studies have shown that PARP7-mediated suppression of type I interferon signaling modulates the severity of EAE, providing a direct link between innate immune regulation and peptide-induced disease (Xu et al., 2025). Additionally, MOG (35-55) administration increases NADPH oxidase and MMP-9 activity, implicating oxidative and matrix remodeling mechanisms in EAE pathology (APExBIO).

Evidence & Benchmarks

• MOG (35-55) induces severe chronic EAE in C57BL/6 and HLA-DR2-transgenic mice when co-administered with CFA, replicating MS-like demyelination (Xu et al., 2025).
• Standard in vivo dosing ranges from 50–150 μg per mouse; higher doses correlate with increased disease incidence and severity (APExBIO).
• In vitro, MOG (35-55) activates T cells at concentrations up to 50 μg/mL, with effects measurable after 48-hour incubation (APExBIO).
• MOG (35-55) stock solutions are stable at -20°C when desiccated and rapidly degrade if left at room temperature (APExBIO).
• PARP7 inhibition restores STAT1/STAT2 levels and type I interferon signaling, attenuating EAE severity in MOG (35-55)-induced models (Xu et al., 2025).

For a detailed comparison of EAE model parameters and troubleshooting strategies, see "Optimizing EAE Models", which complements this article by providing scenario-driven solutions to common laboratory obstacles.

Applications, Limits & Misconceptions

MOG (35-55) is the gold-standard inducer for modeling neuroinflammation and demyelinating autoimmune disease in mice. Its applications extend to screening immunomodulators, dissecting antigen-specific tolerance, and mapping molecular pathways underlying MS. However, it is not a universal model for all forms of demyelination or for non-rodent species. EAE induction with MOG (35-55) is highly strain-dependent, with NOD/Lt and C57BL/6 mice being the most responsive. The peptide’s inability to induce EAE in certain strains or in the absence of CFA is a recognized limitation. Additionally, MOG (35-55) models primarily recapitulate T cell-mediated pathology and may not fully mirror all features of human MS, such as chronic neurodegeneration or reparative remyelination. For a molecular-focused perspective, "MOG (35-55) Peptide: Molecular Control Points" details additional mechanistic checkpoints beyond the scope of this overview.

Common Pitfalls or Misconceptions

• MOG (35-55) is not effective in all mouse strains; genetic susceptibility is critical.
• The peptide does not induce EAE without adjuvant or proper emulsification.
• Stock solutions degrade rapidly if exposed to moisture or room temperature; use fresh preparations for reproducibility.
• MOG (35-55) models T cell-mediated demyelination; it does not capture all aspects of progressive MS, such as neuroaxonal loss.
• Extrapolation to primate or human disease mechanisms requires caution due to immune system differences.

Workflow Integration & Parameters

MOG (35-55) peptide is supplied as a lyophilized powder by APExBIO (SKU A8306). For experimental use, the following protocol parameters maximize reproducibility and biological relevance:

Protocol Parameters

• Stock solution preparation: Dissolve in sterile water at 0.50 mg/mL; apply gentle warming and ultrasonic agitation to enhance solubility (APExBIO).
• Storage: Store desiccated at -20°C; avoid repeated freeze-thaw cycles.
• In vivo dosing (mouse): 50–150 μg per animal, subcutaneously, emulsified in CFA.
• In vitro concentration: 0–50 μg/mL; incubate for up to 48 hours for T cell activation assays.
• Solubility: ≥32.25 mg/mL in water, ≥86 mg/mL in DMSO; insoluble in ethanol.
• Readout: Monitor onset and severity of neurological deficits, measure protein and enzyme activities as needed.

For advanced workflow integration, see "MOG (35-55): Decoding Autoimmune Mechanisms", which extends these recommendations with next-generation assay formats and molecular endpoints.

Conclusion & Outlook

MOG (35-55) remains an essential reagent for dissecting autoimmune mechanisms and testing interventions in MS research. Its robust efficacy, molecular precision, and compatibility with modern immunological assays ensure ongoing relevance. Recent findings implicating PARP7 as a key modulator of type I interferon signaling in MOG (35-55)-induced EAE provide actionable targets for preclinical drug development (Xu et al., 2025). For a summary of how PARP7 inhibition impacts interferon pathways and EAE phenotype, refer to "PARP7 Inhibition Enhances Interferon Signaling and EAE Relief". While the peptide model has defined limits, its contributions to reproducible, mechanistically grounded multiple sclerosis research are unmatched.